Hypoglycemia
Hypoglycemia - Related Videos
01:26
Hypoglycemia
0 Views •
2026
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:15
Hypoglycemia and Glucagon
0 Views •
2024
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
12:08
Improving IV Insulin Administration in a Community Hospital
0 Views •
Cited by 7 •
2012
When compared to the previous paper protocol, implementation of a computerized glucose management system results in a substantial increase in blood glucose concentration measurements within the target range. Using a computerized glucose management system to monitor blood glucose levels, decreases in severe hypoglycemia (<40 mg/dL), clinical hypoglycemia (<70 mg/dL), and hyperglycemia (>180 mg/dL) also can be observed.
01:36
Rabbit Preoperative Preparation, Surgical Procedures, and Postoperative Care
0 Views •
2026
All animal procedures described here must be conducted in accordance with institutional animal ethics guidelines and approved by IACUC. All procedures must follow the principles of the 3Rs—Replacement, Reduction, and Refinement—and must be performed by trained personnel. Preoperative Preparation The initial assessment should include observation of alertness, posture, gait, and grooming behavior, as changes in these parameters may indicate underlying health issues. Body weight should be recorded...
FAQs
A fall in available glucose activates counterregulatory responses, especially the release of glucagon and epinephrine. These hormones oppose the glucose-lowering influence of insulin and help the body respond before neurological impairment becomes severe. Their involvement is important in pharmacology because it shows how drug-induced reductions in glucose interact with the body’s own protective systems.
Hypoglycemia can occur when the glucose-lowering effect of insulin or another medicine exceeds the glucose available to the body. This creates a mismatch between pharmacological action and physiological supply. Studying that mismatch helps identify adverse drug effects and risk factors, which can inform safer prescribing, monitoring, and the design of therapies intended to control glucose more reliably.
The brain and body require glucose to function normally, so a pronounced or prolonged reduction can impair neurological function. This consequence makes hypoglycemia more than a laboratory change: it represents a clinically important adverse effect of excessive glucose-lowering activity. Pharmacological evaluation therefore considers both glucose measurements and the potential functional effects of inadequate glucose availability.
Treatment options include rapidly absorbed carbohydrates, glucagon, and intravenous glucose. These approaches provide ways to restore available glucose or counter the effects of excessive glucose lowering, but the appropriate choice depends on the clinical situation and severity. Their inclusion in pharmacology reflects the need to match an intervention with the urgency of reversing impaired glucose support.
A pharmacological response begins by recognizing that glucose has fallen below the level needed for normal function, then selecting an appropriate glucose-restoring intervention. Rapidly absorbed carbohydrates, glucagon, or intravenous glucose may be used as treatment options. The process also requires attention to the medicine responsible, because identifying an adverse drug effect supports safer subsequent glucose management.
Hypoglycemia is a key outcome when researchers evaluate medicines designed to control blood glucose. Effective therapy must reduce excessive glucose while limiting episodes caused by an imbalance between drug action and available glucose. This pharmacological objective guides the development of treatments that maintain glucose control with fewer hypoglycemic events and improves the safety profile of diabetes care.